Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Cipla, a global pharmaceutical leader, has partnered with ImmunoACT to introduce talicabtagene autoleucel in Africa. This is ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Autoimmune diseases arise when the immune system mistakenly targets and damages the body’s cells and tissues as though they ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...

AstraZeneca will buy AbelZeta Pharma’s 50% share of development and commercialization rights in China for a CAR-T therapy for ...

The acquisition gives AstraZeneca full global control of the therapy’s development, manufacturing and commercialisation.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...